Laurus Labs (BOM:540222) Cyclically Adjusted Revenue per Share: ₹96.18 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540222 Laurus Labs Ltd BOM:540222
66 GF Score
Price ₹1,807.00
GF Value ₹842.42
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Laurus Labs Cyclically Adjusted Revenue per Share?

Laurus Labs BOM:540222 -0.41% 66 Cyclically Adjusted Revenue per Share is ₹96.18 as of Jun. 2026. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹842.42 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Laurus Labs's adjusted revenue per share for the three months ended in Jun. 2026 was ₹37.483. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹96.18 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Laurus Labs's average Cyclically Adjusted Revenue Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-20), Laurus Labs's current stock price is ₹1807.00. Laurus Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹96.18. Laurus Labs's Cyclically Adjusted PS Ratio of today is 18.79.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laurus Labs was 19.29. The lowest was 8.90. And the median was 11.26.


Laurus Labs  (BOM:540222) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Laurus Labs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1807.00/96.18
=18.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laurus Labs was 19.29. The lowest was 8.90. And the median was 11.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Laurus Labs Cyclically Adjusted Revenue per Share Related Terms


Laurus Labs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Laurus Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laurus Labs Cyclically Adjusted Revenue per Share Chart

Laurus Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 92.68

Laurus Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.17 89.45 91.06 92.68 96.18

BOM:540222 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laurus Labs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Laurus Labs's Cyclically Adjusted PS Ratio falls into.


BOM:540222
66GF Score
Laurus Labs Ltd BOM:540222
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laurus Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laurus Labs's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=37.483/167.3573*167.3573
=37.483

Current CPI (Jun. 2026) = 167.3573.

Laurus Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 10.441 105.961 16.491
201612 10.064 105.196 16.011
201703 8.947 105.196 14.234
201706 9.001 107.109 14.064
201709 10.119 109.021 15.534
201712 9.010 109.404 13.783
201803 10.588 109.786 16.140
201806 10.092 111.317 15.173
201809 11.105 115.142 16.141
201812 9.925 115.142 14.426
201903 10.946 118.202 15.498
201906 10.282 120.880 14.235
201909 13.354 123.175 18.144
201912 13.704 126.235 18.168
202003 14.366 124.705 19.280
202006 18.207 127.000 23.993
202009 21.153 130.118 27.207
202012 23.941 130.889 30.611
202103 24.472 131.771 31.081
202106 23.728 134.084 29.616
202109 22.293 135.847 27.464
202112 19.072 138.161 23.102
202203 25.575 138.822 30.832
202206 28.540 142.347 33.554
202209 29.242 144.661 33.830
202212 28.608 145.763 32.846
202303 25.068 146.865 28.566
202306 21.876 150.280 24.362
202309 22.534 151.492 24.894
202312 22.205 152.924 24.301
202403 25.832 153.035 28.250
202406 21.969 155.789 23.600
202409 22.821 157.882 24.191
202412 26.216 158.323 27.712
202503 31.878 157.552 33.862
202506 29.077 159.755 30.461
202509 30.615 162.289 31.571
202512 32.858 163.281 33.678
202603 33.552 164.272 34.182
202606 37.483 167.357 37.483

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹96.18 mean?
Laurus Labs (BOM:540222) has a Cyclically Adjusted Revenue per Share of ₹96.18 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laurus Labs and its competitors.
Is Laurus Labs' Cyclically Adjusted Revenue per Share too high?
Laurus Labs' current Cyclically Adjusted Revenue per Share is ₹96.18. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Cyclically Adjusted Revenue per Share compare to ZTS?
Laurus Labs' Cyclically Adjusted Revenue per Share of ₹96.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laurus Labs and its competitors. Laurus Labs's current Cyclically Adjusted Revenue per Share is ₹96.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹842.42, compared to a current price of ₹1,807.00 — trading 114.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹96.18. Laurus Labs' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Cyclically Adjusted Revenue per Share is ₹96.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laurus Labs (BOM:540222) Overvalued in 2026?

Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued. The current stock price of ₹1,807.00 is trading 114.5% above its estimated GF Value™ of ₹842.42. GuruFocus considers Laurus Labs to be Significantly Overvalued.

Key valuation signals for BOM:540222:

  • Cyclically Adjusted Revenue per Share: ₹96.18
  • GF Value™: ₹842.42 vs. price of ₹1,807.00 (114.5% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laurus Labs Business Description

Other Exchanges LAURUSLABS:India
Address Road No.1, Jubilee Hills, Plot No.103, Hyderabad, TG, IND, 500033
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score

Get the complete analysis for BOM:540222

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,807.00
Price
₹842.42
GF Value